A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Ewing's sarcoma; Rhabdomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 18 Feb 2019 Planned number of patients changed from 30 to 45.
- 21 Aug 2018 Planned End Date changed from 1 Jan 2021 to 30 Jun 2020.
- 21 Aug 2018 Planned primary completion date changed from 1 Jun 2020 to 30 Jun 2020.